睿知中国医院研究地图
候选清单

即将招募肝细胞癌不分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由四川大学华西医院牵头,本站收录的另外 8 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 80 岁;性别:不限

    登记记录的入选字段

  2. HCC confirmed by histology or cytology or diagnosed according to accepted clinical diagnostic criteria. Histologic or cytologic confirmation is generally required for participants without cirrhosis.

    入选标准第 3 条

  3. Child-Pugh class A and indocyanine green retention rate at 15 minutes (ICG R15) <30%.

    入选标准第 9 条

  4. Previous treatment with a PD-1/PD-L1 inhibitor combined with a targeted or anti-angiogenic agent, with or without locoregional treatment such as transarterial chemoembolization, hepatic arterial infusion chemotherapy, radiotherapy, or ablation.

    入选标准第 5 条

  5. Eastern Cooperative Oncology Group performance status of 0 or 1.

    入选标准第 13 条

  6. Hemoglobin >=90 g/L;

    入选标准第 15 条

    Absolute neutrophil count >=1.5 x 10\^9/L;

    入选标准第 16 条

    Platelet count >=60 x 10\^9/L;

    入选标准第 17 条

    Total bilirubin <=1.5 times the upper limit of normal (ULN);

    入选标准第 18 条

    AST, ALT, and alkaline phosphatase <=2.5 times the ULN;

    入选标准第 19 条

    Serum creatinine <=1.5 times the ULN or endogenous creatinine clearance >=50 mL/min;

    入选标准第 20 条

    No active bleeding, with international normalized ratio <=1.5 times the ULN and activated partial thromboplastin time <=1.5 times the ULN.

    入选标准第 22 条

  7. Another active malignancy within the previous 5 years, except for a malignancy treated with curative intent and considered to have a low risk of recurrence, such as carcinoma in situ of the cervix or nonmelanoma skin cancer.

    排除标准第 12 条

  8. Women of childbearing potential must have a negative pregnancy test before randomization and agree to use effective contraception during study treatment and for the required period after the last dose. Nonsterilized men with partners of childbearing potential must also agree to use effective contraception.

    入选标准第 26 条

    Pregnancy or breastfeeding.

    排除标准第 11 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07866612,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntary participation and provision of written informed consent.
  2. Age 18 to 80 years, inclusive.
  3. HCC confirmed by histology or cytology or diagnosed according to accepted clinical diagnostic criteria. Histologic or cytologic confirmation is generally required for participants without cirrhosis.
  4. No definite extrahepatic metastasis before initiation of the anticancer treatment that resulted in the current radiologic complete response (rCR).
  5. Previous treatment with a PD-1/PD-L1 inhibitor combined with a targeted or anti-angiogenic agent, with or without locoregional treatment such as transarterial chemoembolization, hepatic arterial infusion chemotherapy, radiotherapy, or ablation.
  6. Continued use of the same systemic regimen between the first documented rCR and confirmatory imaging. Dose modification or temporary interruption for toxicity is permitted, but changing treatment because of insufficient efficacy is not permitted.
  7. rCR confirmed according to mRECIST by repeat imaging performed 4 to 8 weeks after the first documented rCR.
  8. Multidisciplinary team assessment confirming that curative-intent liver resection is medically and technically feasible, R0 resection is expected to be achievable, and perioperative risk is acceptable.
  9. Child-Pugh class A and indocyanine green retention rate at 15 minutes (ICG R15) <30%.
  10. Future liver remnant (FLR) generally >=40% of standard liver volume (SLV) for participants with chronic liver disease, substantial hepatic parenchymal injury, or cirrhosis, and generally >=30% of SLV for participants without substantial fibrosis or cirrhosis.
  11. Pretreatment tumor thrombus involving the portal vein, hepatic vein, and/or inferior vena cava is permitted, but atrial tumor thrombus is not permitted. Previously present macrovascular tumor thrombus must show no definite radiologic activity after treatment and must be considered completely resectable by the multidisciplinary team.
  12. No extrahepatic metastasis or other active HCC lesion on contrast-enhanced CT and/or MRI of the chest, abdomen, and pelvis before randomization.
  13. Eastern Cooperative Oncology Group performance status of 0 or 1.
  14. Adequate organ function before randomization, including:
  15. Hemoglobin >=90 g/L;
  16. Absolute neutrophil count >=1.5 x 10\^9/L;
  17. Platelet count >=60 x 10\^9/L;
  18. Total bilirubin <=1.5 times the upper limit of normal (ULN);
  19. AST, ALT, and alkaline phosphatase <=2.5 times the ULN;
  20. Serum creatinine <=1.5 times the ULN or endogenous creatinine clearance >=50 mL/min;
  21. Urine protein <2+, or 24-hour urinary protein <1.0 g.
  22. No active bleeding, with international normalized ratio <=1.5 times the ULN and activated partial thromboplastin time <=1.5 times the ULN.
  23. Participants with hepatitis B virus infection must receive appropriate antiviral treatment according to local standards and agree to continue treatment during the study. Participants with an indication for antiviral treatment must start treatment during screening if they are not already receiving it.
  24. Participants with hepatitis C virus antibodies must undergo hepatitis C virus RNA testing and must not have active hepatitis C virus infection.
  25. Medically eligible for both surgical consolidation and continued systemic maintenance therapy and willing to receive the randomly assigned strategy.
  26. Women of childbearing potential must have a negative pregnancy test before randomization and agree to use effective contraception during study treatment and for the required period after the last dose. Nonsterilized men with partners of childbearing potential must also agree to use effective contraception.

排除标准:Exclusion Criteria:

  1. Fibrolamellar HCC, sarcomatoid HCC, combined hepatocellular-cholangiocarcinoma, or another atypical HCC histologic subtype.
  2. Definite extrahepatic metastasis before initiation of the treatment that resulted in the current rCR, or any extrahepatic metastasis identified before randomization.
  3. Inability to undergo safe curative liver resection, an expectation that R0 resection cannot be achieved, or another medical factor that prevents surgical consolidation.
  4. Previous liver transplantation or current plans for liver transplantation.
  5. Decompensated cirrhosis or Child-Pugh class B or C hepatic function.
  6. Clinically significant and uncontrolled portal hypertension or another condition that substantially increases the perioperative risk of liver resection, including recurrent gastroesophageal variceal bleeding or refractory ascites.
  7. Active gastrointestinal bleeding within 4 weeks before randomization or a coagulation disorder that continues to fall outside study requirements after appropriate correction.
  8. Active infection, sepsis, or another serious infectious disease requiring systemic anti-infective treatment that may affect the safety of surgery or systemic therapy.
  9. Previous immune-related adverse events not recovered to Grade 1 or lower that may affect the safety of surgery or continued systemic treatment. Stable endocrine immune-related adverse events controlled with replacement therapy are permitted.
  10. Severe cardiac, pulmonary, renal, or other major organ dysfunction, or another serious comorbidity that would prevent tolerance of curative liver resection and/or continued systemic treatment.
  11. Pregnancy or breastfeeding.
  12. Another active malignancy within the previous 5 years, except for a malignancy treated with curative intent and considered to have a low risk of recurrence, such as carcinoma in situ of the cervix or nonmelanoma skin cancer.
  13. Inability to undergo standardized multiphase contrast-enhanced CT or MRI, or a condition that may substantially interfere with accurate radiologic assessment.
  14. A medical, psychological, social, or adherence-related factor that would prevent receipt of either randomized treatment strategy.
  15. Any other condition that, in the investigator's judgment, may affect participant safety, study adherence, or the reliability of study results and makes the individual unsuitable for participation.

引自 ClinicalTrials.gov, NCT07866612, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07866612,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07866612